Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
相关临床试验
34
13 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
2015
进行中（未招募）
11
32.4%
已完成
4
11.8%
Enrolling By Invitation
1
2.9%
尚未招募
1
2.9%
招募中
12
35.3%
暂停
2
5.9%
终止
1
2.9%
Unknown
1
2.9%
撤回
1
2.9%
- The FDA confirmed a 12-patient pivotal efficacy population for RP-A501 in Danon disease, with the first three patients treated under the modified protocol counting toward that total. - Rocket Pharmaceuticals must enroll and dose nine additional male patients at the recalibrated dose of 3.8 x 10^13 genome copies per kilogram using commercial-grade product. - The trial retains 12-month co-primary endpoints of myocardial LAMP2 protein expression and a 10% reduction in left ventricular mass index, intended to support accelerated approval. - No clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome was observed in the first three patients, all of whom completed at least four weeks of follow-up.
- Analysis of FDA Complete Response Letters from 2020 to 2024 reveals that 74% cited manufacturing or quality issues, pointing to organizational deficiencies rather than scientific failure as the primary constraint in drug development. - Three advanced therapy programs received CRLs on a single day in July 2025 — all for CMC deficiencies — underscoring a structural mismatch between how companies make capital commitment decisions and what compressed timelines now demand. - With 57% of 2024 FDA novel drug approvals involving expedited designations and AI compressing discovery timelines, companies must restructure manufacturing scale-up decisions, embed commercial functions earlier, and develop integrated leadership capable of decision-making under uncertainty. - Mid-sized biopharma companies face the greatest exposure, while therapeutic areas beyond oncology — including cardiovascular, CNS, metabolic disease, and immunology — remain largely unprepared for the accelerating development paradigm.
- The Institute for Clinical and Economic Review (ICER) released a report recommending greater transparency in the FDA's accelerated approval pathway for drugs treating serious conditions with no approved treatments. - The report proposes implementing a scoring system for clinical trial quality, requiring advisory committees for reviews, and strengthening surrogate endpoint selection to improve pathway performance. - Recent accelerated approvals include Denali Therapeutics' Avlayah for rare disease and Rocket Pharmaceuticals' gene therapy Kresladi, while controversial cases like Biogen's withdrawn Aduhelm highlight ongoing concerns about evidence standards.
- Rocket Pharmaceuticals voluntarily withdrew its FDA Biologics License Application for RP-L102 (mozafancogene autotemcel), a gene therapy for Fanconi anemia, following a similar withdrawal in the EU in July 2025. - The decision reflects business and strategic considerations as the company focuses on programs with clearer regulatory and commercial pathways, not safety or efficacy concerns. - RP-L102 was positioned as the first alternative to allogeneic hematopoietic stem cell transplantation for Fanconi anemia type A, targeting patients with FANCA gene mutations. - The company remains open to future partnerships to advance the therapy and preserves the option to re-engage with regulators later.
- Rocket Pharmaceuticals is laying off 80 employees, representing 30% of its workforce, to reduce cash burn by almost 25% and extend its runway into 2027. - The company is narrowing its pipeline focus to prioritize late-stage cardiovascular gene therapies for Danon disease and cardiomyopathy conditions following regulatory setbacks. - The strategic realignment comes after an FDA clinical hold on its pivotal Danon disease trial following a patient death and previous rejection of its Kresladi gene therapy. - Rocket's hematology programs, including RP-L102 for Fanconi anemia previously targeted for 2025 approval, face significant delays as resources shift to cardiovascular assets.
- Over 180 companies are actively developing more than 250 AAV-based gene therapies, representing a robust pipeline for treating genetic disorders including hemophilia, spinal muscular atrophy, and inherited retinal diseases. - Recent FDA approvals include Roctavian for severe hemophilia A and Elevidys for Duchenne muscular dystrophy, demonstrating the therapeutic potential of AAV vectors in addressing rare genetic conditions. - The field has experienced notable setbacks, including Pfizer's termination of its hemophilia A partnership and a patient death linked to Elevidys treatment, highlighting ongoing safety challenges. - Leading pipeline candidates include DTX401 for glycogen storage disease, SRP-9003 for limb-girdle muscular dystrophy, and several innovative therapies targeting retinal diseases and cardiovascular conditions.
- NodThera has appointed Elisabeth Björk, M.D., Ph.D., former Senior Vice President at AstraZeneca's obesity franchise, to its Board of Directors. - The appointment follows the commencement of NodThera's Phase 2 RESOLVE-1 trial evaluating oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity. - Björk brings over 20 years of experience in late-stage clinical development and commercialization, particularly in cardiovascular and metabolic diseases. - NodThera is developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases through selective modulation of metabolic pathways.
- The FDA placed a clinical hold on Rocket Pharmaceuticals' Phase 2 pivotal trial for RP-A501, a gene therapy for Danon disease, following a patient death from a serious adverse event. - Rocket Pharmaceuticals' stock price crashed over 60% on May 27, 2025, after the company disclosed the FDA's clinical hold and revealed undisclosed protocol amendments. - A securities class action lawsuit has been filed alleging the company failed to properly disclose safety risks and protocol changes, including the addition of a novel immunomodulatory agent. - The lawsuit claims Rocket Pharmaceuticals made materially false statements about RP-A501's safety profile and trial protocol while knowing serious adverse events were at risk.
- The FDA has placed a clinical hold on Rocket Pharmaceuticals' Phase II gene therapy trial for RP-A501 after a patient developed capillary leak syndrome and subsequently died. - The patient experienced serious complications including fluid leaking from blood vessels into surrounding tissues, causing swelling and low blood pressure, followed by an acute systemic infection. - Rocket is investigating whether a novel immune suppression agent recently added to the pre-treatment regimen may have contributed to the adverse event. - The company's stock tumbled 63% in premarket trading, and analysts estimate the clinical hold could take weeks to months to resolve.
• REGENXBIO has closed a non-dilutive royalty bond agreement with Healthcare Royalty for up to $250 million, receiving $150 million upfront that extends its cash runway into early 2027. • The deal monetizes select royalties from ZOLGENSMA for SMA and payments from gene therapies for MPS disorders, while REGENXBIO retains other funding opportunities including a potential Priority Review Voucher. • This strategic financing supports REGENXBIO's late-stage pipeline development, including RGX-121 for MPS II, RGX-202 for Duchenne muscular dystrophy, and ABBV-RGX-314 for wet AMD.
